First Tracks Stock Rises Before Early-Stage Trial Data Review
First Tracks Biotherapeutics shares gained 15% after the company announced a Monday review of trial data for its celiac disease drug ANB033.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Shares of First Tracks Biotherapeutics moved higher after the company said it would present top-line results from a celiac disease treatment trial on Monday. The stock was up 15% at $36.71 in premarket trading. By the end of Friday’s session, the shares had gained nearly 68% since the start of the year.
Dow Jones Newswires reported that the company announced late Friday plans for an investor conference call and live webcast covering data from the first cohort of an early-stage study of ANB033 in celiac disease. The event is scheduled to begin at 8:30 a.m. Eastern on Monday.
why it matters
The data review is a near-term event that could shape how investors assess progress on First Tracks’ ANB033 program. The premarket move signals heightened market attention, although the report does not provide results on the drug’s efficacy or safety.
instruments
sources
- First Tracks Shares Climb Ahead of Early-Stage Trial Readout — Dow Jones Newswires, 12 October 2026 at 10:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗